DOCS vs. TAK: A Head-to-Head Stock Comparison

Updated on October 16, 2025

Here’s a clear look at DOCS and TAK, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

DOCS is a standard domestic listing, while TAK trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.

Symbol	DOCS	TAK
Company Name	Doximity, Inc.	Takeda Pharmaceutical Company Limited
Country	United States	Japan
GICS Sector	Health Care	Health Care
GICS Industry	Health Care Technology	Pharmaceuticals
Market Capitalization	13.77 billion USD	45.23 billion USD
Exchange	NYSE	NYSE
Listing Date	June 24, 2021	January 5, 2010
Security Type	Common Stock	ADR

Historical Performance

This chart compares the performance of DOCS and TAK by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

DOCS vs. TAK: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	DOCS	TAK
5-Day Price Return	1.05%	1.37%
13-Week Price Return	16.12%	-1.89%
26-Week Price Return	23.18%	-3.39%
52-Week Price Return	62.86%	5.51%
Month-to-Date Return	-2.42%	0.95%
Year-to-Date Return	33.70%	4.19%
10-Day Avg. Volume	1.42M	5.10M
3-Month Avg. Volume	1.67M	4.35M
3-Month Volatility	41.50%	19.26%
Beta	1.39	0.43

Profitability

Return on Equity (TTM)

DOCS

22.94%

Health Care Technology Industry

Max: 48.09%
Q3: 41.80%
Median: 18.17%
Q1: 11.64%
Min: 11.05%

DOCS’s Return on Equity of 22.94% is on par with the norm for the Health Care Technology industry, indicating its profitability relative to shareholder equity is typical for the sector.

TAK

1.95%

Pharmaceuticals Industry

Max: 38.59%
Q3: 19.84%
Median: 11.85%
Q1: 5.40%
Min: -10.91%

TAK’s Return on Equity of 1.95% is in the lower quartile for the Pharmaceuticals industry. This indicates a less efficient generation of profit from its equity base when compared to its competitors.

DOCS vs. TAK: A comparison of their Return on Equity (TTM) against their respective Health Care Technology and Pharmaceuticals industry benchmarks.

Net Profit Margin (TTM)

DOCS

39.88%

Health Care Technology Industry

Max: 52.24%
Q3: 49.15%
Median: 33.59%
Q1: 16.86%
Min: 13.38%

DOCS’s Net Profit Margin of 39.88% is aligned with the median group of its peers in the Health Care Technology industry. This indicates its ability to convert revenue into profit is typical for the sector.

TAK

3.06%

Pharmaceuticals Industry

Max: 40.67%
Q3: 19.07%
Median: 12.31%
Q1: 4.50%
Min: -9.91%

Falling into the lower quartile for the Pharmaceuticals industry, TAK’s Net Profit Margin of 3.06% indicates weaker profitability. This means the company retains a smaller portion of each dollar in sales as profit compared to its competitors.

DOCS vs. TAK: A comparison of their Net Profit Margin (TTM) against their respective Health Care Technology and Pharmaceuticals industry benchmarks.

Operating Profit Margin (TTM)

DOCS

40.07%

Health Care Technology Industry

Max: 74.05%
Q3: 65.56%
Median: 33.50%
Q1: 22.83%
Min: 21.46%

DOCS’s Operating Profit Margin of 40.07% is around the midpoint for the Health Care Technology industry, indicating that its efficiency in managing core business operations is typical for the sector.

TAK

8.05%

Pharmaceuticals Industry

Max: 45.78%
Q3: 23.14%
Median: 16.68%
Q1: 7.98%
Min: -7.13%

TAK’s Operating Profit Margin of 8.05% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.

DOCS vs. TAK: A comparison of their Operating Profit Margin (TTM) against their respective Health Care Technology and Pharmaceuticals industry benchmarks.

Profitability at a Glance

Symbol	DOCS	TAK
Return on Equity (TTM)	22.94%	1.95%
Return on Assets (TTM)	19.76%	0.95%
Net Profit Margin (TTM)	39.88%	3.06%
Operating Profit Margin (TTM)	40.07%	8.05%
Gross Profit Margin (TTM)	90.14%	64.78%

Financial Strength

Current Ratio (MRQ)

DOCS

6.47

Health Care Technology Industry

Max: 6.49
Q3: 6.49
Median: 6.02
Q1: 3.62
Min: 2.96

DOCS’s Current Ratio of 6.47 aligns with the median group of the Health Care Technology industry, indicating that its short-term liquidity is in line with its sector peers.

TAK

1.16

Pharmaceuticals Industry

Max: 4.65
Q3: 2.64
Median: 1.85
Q1: 1.26
Min: 0.78

TAK’s Current Ratio of 1.16 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

DOCS vs. TAK: A comparison of their Current Ratio (MRQ) against their respective Health Care Technology and Pharmaceuticals industry benchmarks.

Debt-to-Equity Ratio (MRQ)

DOCS

0.00

Health Care Technology Industry

Max: 0.14
Q3: 0.10
Median: 0.01
Q1: 0.00
Min: 0.00

Falling into the lower quartile for the Health Care Technology industry, DOCS’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.

TAK

0.66

Pharmaceuticals Industry

Max: 1.75
Q3: 0.82
Median: 0.35
Q1: 0.13
Min: 0.00

TAK’s Debt-to-Equity Ratio of 0.66 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

DOCS vs. TAK: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Health Care Technology and Pharmaceuticals industry benchmarks.

Interest Coverage Ratio (TTM)

DOCS

Health Care Technology Industry

Max: 224.12
Q3: 224.12
Median: 219.00
Q1: 219.00
Min: 219.00

Interest Coverage Ratio data for DOCS is currently unavailable.

TAK

1.96

Pharmaceuticals Industry

Max: 103.95
Q3: 43.60
Median: 9.83
Q1: 2.37
Min: -42.71

In the lower quartile for the Pharmaceuticals industry, TAK’s Interest Coverage Ratio of 1.96 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.

DOCS vs. TAK: A comparison of their Interest Coverage Ratio (TTM) against their respective Health Care Technology and Pharmaceuticals industry benchmarks.

Financial Strength at a Glance

Symbol	DOCS	TAK
Current Ratio (MRQ)	6.47	1.16
Quick Ratio (MRQ)	6.20	0.59
Debt-to-Equity Ratio (MRQ)	0.00	0.66
Interest Coverage Ratio (TTM)	--	1.96

Growth

Revenue Growth

DOCS vs. TAK: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

DOCS vs. TAK: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

DOCS

0.00%

Health Care Technology Industry

Max: 0.89%
Q3: 0.70%
Median: 0.15%
Q1: 0.04%
Min: 0.00%

DOCS currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

TAK

4.48%

Pharmaceuticals Industry

Max: 7.14%
Q3: 3.45%
Median: 2.17%
Q1: 0.33%
Min: 0.00%

With a Dividend Yield of 4.48%, TAK offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.

DOCS vs. TAK: A comparison of their Dividend Yield (TTM) against their respective Health Care Technology and Pharmaceuticals industry benchmarks.

Dividend Payout Ratio (TTM)

DOCS

0.00%

Health Care Technology Industry

Max: 101.92%
Q3: 87.10%
Median: 42.63%
Q1: 10.66%
Min: 0.00%

DOCS has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

TAK

124.94%

Pharmaceuticals Industry

Max: 199.58%
Q3: 97.17%
Median: 53.47%
Q1: 22.97%
Min: 0.00%

TAK’s Dividend Payout Ratio of 124.94% is in the upper quartile for the Pharmaceuticals industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.

DOCS vs. TAK: A comparison of their Dividend Payout Ratio (TTM) against their respective Health Care Technology and Pharmaceuticals industry benchmarks.

Dividend at a Glance

Symbol	DOCS	TAK
Dividend Yield (TTM)	0.00%	4.48%
Dividend Payout Ratio (TTM)	0.00%	124.94%

Valuation

Price-to-Earnings Ratio (TTM)

DOCS

58.58

Health Care Technology Industry

Max: 280.41
Q3: 225.12
Median: 59.01
Q1: 44.08
Min: 39.20

DOCS’s P/E Ratio of 58.58 is within the middle range for the Health Care Technology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

TAK

50.48

Pharmaceuticals Industry

Max: 45.19
Q3: 27.91
Median: 20.59
Q1: 15.08
Min: 3.79

At 50.48, TAK’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Pharmaceuticals industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

DOCS vs. TAK: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Health Care Technology and Pharmaceuticals industry benchmarks.

Price-to-Sales Ratio (TTM)

DOCS

23.36

Health Care Technology Industry

Max: 146.49
Q3: 115.78
Median: 19.83
Q1: 7.94
Min: 5.25

DOCS’s P/S Ratio of 23.36 aligns with the market consensus for the Health Care Technology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

TAK

1.54

Pharmaceuticals Industry

Max: 8.87
Q3: 4.56
Median: 2.14
Q1: 1.58
Min: 0.11

In the lower quartile for the Pharmaceuticals industry, TAK’s P/S Ratio of 1.54 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

DOCS vs. TAK: A comparison of their Price-to-Sales Ratio (TTM) against their respective Health Care Technology and Pharmaceuticals industry benchmarks.

Price-to-Book Ratio (MRQ)

DOCS

11.22

Health Care Technology Industry

Max: 115.01
Q3: 89.07
Median: 9.11
Q1: 4.04
Min: 3.06

DOCS’s P/B Ratio of 11.22 is within the conventional range for the Health Care Technology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

TAK

1.03

Pharmaceuticals Industry

Max: 9.78
Q3: 4.99
Median: 2.48
Q1: 1.53
Min: 0.59

TAK’s P/B Ratio of 1.03 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

DOCS vs. TAK: A comparison of their Price-to-Book Ratio (MRQ) against their respective Health Care Technology and Pharmaceuticals industry benchmarks.

Valuation at a Glance

Symbol	DOCS	TAK
Price-to-Earnings Ratio (TTM)	58.58	50.48
Price-to-Sales Ratio (TTM)	23.36	1.54
Price-to-Book Ratio (MRQ)	11.22	1.03
Price-to-Free Cash Flow Ratio (TTM)	47.94	8.45